Boston – CBRE announced that Tango Therapeutics has signed a lease for a new headquarters location at 201 Brookline Avenue in Boston, Massachusetts.
Tango Therapeutics will occupy 65,000 sq. ft. and will relocate from 22,000 sq. ft. at 100 Binney Street. CBRE’s Jon Varholak, Eric Smith and McKenna Teague represented Tango Therapeutics.
“201 Brookline Avenue will provide us with growth opportunities, state-of-the-art technology, collaboration spaces, and access to Fenway’s exciting amenities, all while staying in one of Boston’s new life science clusters,” said CEO Barbara Weber.
Founded in 2017, Tango Therapeutics is a biotechnology company that develops cancer medicines focused on tumor suppressor gene loss, immune evasion and unmarked oncogenes.
Situated within Boston’s amenity-rich Fenway neighborhood, 201 Brookline Avenue is currently being developed and will be a 500,000-sq.-ft., Class A lab and office building.